InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,011.12
(
-0.22%
)
US TECH 100
16,918.00
(
-0.68%
)
Dow Jones
37,775.38
(
0.06%
)
Brent Oil
86.39
(
-0.68%
)
Bitcoin
63,485.30
(
3.59%
)
Post# of 251520
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 825
Posts 119429
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 159024

Saturday, 06/22/2013 6:38:05 PM

Saturday, June 22, 2013 6:38:05 PM

Post# of 251520
ABBV/ENTA will start a phase-1 trial of ABT-493 (ENTA’s next-gen PI, which is licensed to ABBV) + ABT-530 (ABBV’s own next-generation NS5A) in 3Q13. Unlike ABT-450, ABT-493 does not require ritonavir boosting and it is small enough to be combined with ABT-530 in a single qD tablet.

The combination may have utility beyond genotype-1, although the companies have not yet made specific claims. (Source: ENTA’s recent WF webcast.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up